AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

RESVERATROL AND ITS BENEFITS

 Uncategorized  Comments Off on RESVERATROL AND ITS BENEFITS
May 272013
 

SEE MY PRESENTATION

Links

 

http://newdrugapprovals.wordpress.com/2013/05/27/resveratrol-and-its-benefits-my-presentation-on-slideshare/

OR

http://www.slideshare.net/anthonycrasto64/anthony-crasto-resveratrol-synthesis-and-benefits

Share

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

 Phase 3 drug, Uncategorized  Comments Off on Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
May 262013
 

PREDADENANT

 

Links

http://newdrugapprovals.wordpress.com/2013/05/26/merck-provides-update-on-phase-iii-clinical-program-for-preladenant-the-companys-investigational-parkinsons-disease-medicine/

Share

Sanofi and Regeneron’s dupilumab for asthma. The partners have unveiled Phase IIa data at the American Thoracic Society meeting in Philadelphia on dupilumab, an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation

 Uncategorized  Comments Off on Sanofi and Regeneron’s dupilumab for asthma. The partners have unveiled Phase IIa data at the American Thoracic Society meeting in Philadelphia on dupilumab, an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation
May 232013
 

read all

http://newdrugapprovals.wordpress.com/2013/05/23/sanofi-and-regeneron-looksanofi-and-regenerons-dupilumab-for-asthma-the-partners-have-unveiled-phase-iia-data-at-the-american-thoracic-society-meeting-in-philadelphia-on-dupilumab-an-interleukin/

Share
 Older Entries  Newer Entries
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: